Search

Displaying results 5801 - 5810 of 7283 in total
  1. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  2. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  3. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  4. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  5. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

  6. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.

  7. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia. … In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult.

  8. Drug

    SNX-5422

    go.drugbank.com/drugs/DB06070
    Investigational

    SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. … As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

  9. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

  10. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels